Paul Matteis
Stock Analyst at Stifel
(3.10)
# 1,311
Out of 5,105 analysts
128
Total ratings
47.67%
Success rate
0.77%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Buy | $50 → $40 | $19.51 | +105.02% | 3 | Dec 11, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $183 → $188 | $152.80 | +23.04% | 11 | Dec 11, 2025 | |
| LBRX LB Pharmaceuticals | Maintains: Buy | $27 → $35 | $19.13 | +83.01% | 2 | Dec 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $36 → $39 | $19.27 | +102.39% | 5 | Dec 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $495 → $508 | $397.55 | +27.78% | 16 | Dec 11, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $24 → $25 | $27.15 | -7.92% | 6 | Dec 11, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $28 | $20.70 | +35.27% | 1 | Nov 21, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Hold | $2 → $3 | $2.09 | +43.54% | 3 | Nov 17, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Hold | $73 → $61 | $53.31 | +14.43% | 11 | Nov 6, 2025 | |
| BIIB Biogen | Upgrades: Buy | $144 → $202 | $174.10 | +16.03% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $455 → $445 | $452.04 | -1.56% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $43 → $67 | $80.82 | -17.10% | 6 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $5.66 | +112.01% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $94 | $113.56 | -17.22% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $42.77 | -25.18% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $13.04 | +145.49% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $6.74 | +63.20% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.49 | +168.46% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $15.13 | -33.91% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $20.92 | +186.81% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $28.50 | +26.32% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $30.27 | +15.63% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $11.63 | +149.36% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $9.77 | +104.71% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.25 | +182.35% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $360 → $50 | $3.92 | +1,175.51% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $16.91 | +89.24% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.14 | +1,161.68% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $21.36 | -34.46% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $16.56 | +286.47% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $220.65 | +54.09% | 1 | Dec 21, 2016 |
uniQure
Dec 11, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $19.51
Upside: +105.02%
Neurocrine Biosciences
Dec 11, 2025
Maintains: Buy
Price Target: $183 → $188
Current: $152.80
Upside: +23.04%
LB Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $27 → $35
Current: $19.13
Upside: +83.01%
Dyne Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $19.27
Upside: +102.39%
Alnylam Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $495 → $508
Current: $397.55
Upside: +27.78%
ACADIA Pharmaceuticals
Dec 11, 2025
Maintains: Hold
Price Target: $24 → $25
Current: $27.15
Upside: -7.92%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $28
Current: $20.70
Upside: +35.27%
Neumora Therapeutics
Nov 17, 2025
Maintains: Hold
Price Target: $2 → $3
Current: $2.09
Upside: +43.54%
BioMarin Pharmaceutical
Nov 6, 2025
Downgrades: Hold
Price Target: $73 → $61
Current: $53.31
Upside: +14.43%
Biogen
Nov 6, 2025
Upgrades: Buy
Price Target: $144 → $202
Current: $174.10
Upside: +16.03%
Nov 4, 2025
Maintains: Hold
Price Target: $455 → $445
Current: $452.04
Upside: -1.56%
Oct 6, 2025
Maintains: Hold
Price Target: $43 → $67
Current: $80.82
Upside: -17.10%
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $5.66
Upside: +112.01%
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $113.56
Upside: -17.22%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $42.77
Upside: -25.18%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $13.04
Upside: +145.49%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $6.74
Upside: +63.20%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.49
Upside: +168.46%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $15.13
Upside: -33.91%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $20.92
Upside: +186.81%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $28.50
Upside: +26.32%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $30.27
Upside: +15.63%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $11.63
Upside: +149.36%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $9.77
Upside: +104.71%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $4.25
Upside: +182.35%
Jun 23, 2022
Downgrades: Hold
Price Target: $360 → $50
Current: $3.92
Upside: +1,175.51%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $16.91
Upside: +89.24%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $2.14
Upside: +1,161.68%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $21.36
Upside: -34.46%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $16.56
Upside: +286.47%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $220.65
Upside: +54.09%